Navigation Links
New treatment gives hope for pulmonary fibrosis patients

ATS 2008, TORONTOPatients with idiopathic pulmonary fibrosis (IPF) may have a new treatment option, according to researchers in Japan.

In a Phase III, double-blind, placebo-controlled clinical trial, the investigators discovered that a daily dose of pirfenidone could slow the progression of IPF, reducing the loss of lung capacity. The results will be announced at the American Thoracic Societys 2008 International Conference in Toronto on Tuesday, May 20.

The most common treatment for IPF is anti-inflammatory agents such as steroids, said lead researcher Takashi Ogura, M.D., of Kanagawa Cardiovascular and Respiratory Center in Yokohama, Japan. However our study confirmed that pirfenidone, the main action of which is thought to be antifibrotic, achieved a therapeutic effect on IPF. I expect that our study will serve as a guide to develop a new therapy for IPF in the future.

The researchers recruited a total of 275 Japanese patients with mild to moderate IPF and randomized them to a high dose pirfenidone (1,800 mg/day) group, a low dose pirfenidone group (1,200 mg/day) and a placebo group. They measured lung capacity (vital capacity or VC) and progression-free survival, defined as a period without death or a greater than 10 percent decrease in VC, to determine the effectiveness of the regimens.

At the end of one year, they found that patients who had been randomized to the high dose regimen had significantly lower loss of VC than the placebo group. Furthermore, pirfenidone slowed the overall deterioration of IPF compared to the placebo.

Taken altogether, our study demonstrated positive clinical effects of pirfenidone that suppresses the progress of IPF and potentially contributes to improving the outcomes of patients with IPF, said Dr. Ogura.

Pirfenidone represents new hope, not only for IPF patients who currently have no curative treatment options, but because it is thought to be an antifibrotic agent, it may be able to treat other fibrotic lung diseases, such as interstitial pneumonia with collagen vascular disease and extrapulmonary fibrosis.

We will continue the follow-up of the patient cohort included in this study to identify whether pirfenidone can contribute to prolonged survival in patients with IPF, said Dr. Ogura. Other clinical studies of pirfenidone are also being conducted in the U.S. and Europe, and we hope that our results will be replicated there.


Contact: Keely Savoie
American Thoracic Society

Related medicine news :

1. Mission Pharmacal Launches Ferralet(R) 90 for Treatment of the Leading Cause of Anemia in the U.S.
2. Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa
3. Mapping of prostate cancer genes opens the door to new treatments
4. Many Diabetics Dont Get Necessary Blood Pressure Treatment
5. MR imaging accurately determines prostate cancer treatment failure
6. Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment
7. Old antibiotic may find new life as a stroke treatment
8. Radiofrequency ablation is effective treatment for dysplasia in Barretts esophagus
9. New Hair Loss Treatment Proves Effectiveness
10. Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome
11. Advances Aid Treatment, Diagnosis of Celiac Disease
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... VVA (PRWEB) , ... November 27, 2015 , ... ... motto of progress through sharing, the 2016 Building Better Radiology Marketing ... The conference will begin on Sunday, March 6, 2016, at Caesars Palace in ...
(Date:11/27/2015)... ... 2015 , ... Keeping in mind challenges faced by parents ... consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for children ... and bring advice from parenting experts within their reach. As a part of ...
(Date:11/27/2015)... ... 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces ... This is one of Joplin's most famous and beautiful concert posters. The concert was ... in Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's ...
(Date:11/26/2015)... and Cambridge, ON (PRWEB) , ... November 26, ... ... the availability of a real-time eReferral system for diagnostic imaging in the Waterloo ... X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical record ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Niederlande, November 27, 2015 ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   Clinical ... --> Clinical Cancer Research vom ...
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... november 2015 AAIPharma Services Corp./Cambridge ... investering aan van ten minste $15,8 miljoen ... het mondiale hoofdkantoor in Wilmington, ... in extra kantoorruimte en extra capaciteit voor ... behoeften van de farmaceutische en biotechnologische markten. ...
Breaking Medicine Technology: